| Technology Overview　GM-01 |
| Technology |
Combination of Gene Therapy and Immunotherapy for the Treatment of orthotropic liver tumors |
| Mechanism |
Combine anti-angiogenesis & immunotherapy via adenoviral vector with cytokine genes which lead to the shrinkage of liver tumor size |
| Indication |
Primary, multifocal hepatocellular carcinoma (HCC) |
| Efficacy |
In vivo |
Combination therapy (anti-angiogenesis + immunotherapy)
shows synergetic therapeutic effects than either alone (inoculated tumor & multi-focal HCC mice, HCC rat)
Immunotherapy with GM-CSF + IL-12 increase survival rate.
Tumor size reduction (HCC mice, HCC woodchuck)
|
| Development Stage |
Pre-clinical stage |
| Intellectual Property |
U.S Provisional 60/957865 (filed@2007/8/24), TW Patent 96/3/735 (filed@2007/8/27) |
| Collaboration Opportunity |
Technology licensing, Co-development, Research collaboration |
